Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Exposure to epcoritamab is associated with improved T-cell functionality and dynamic changes in CD8+ T-cells in diffuse large B-cell lymphoma: Insights from epcore NHL-6

Gregory Takacs, Pingping Zheng, Danqing Xu, Valerie Robinson, David Sharon, Yoshiko Hashikawa, David Andorsky, Rakhee Vaidya, Adelba Torres, Kojo Osei-Bonsu, Kristin Conte, Edith Szafer Glusman, Wei Liu, PK Epling-Burnette, Neha Dixit

Blood (2025) 146 (Supplement 1): 3566.

https://doi.org/10.1182/blood-2025-3566

Published: 2025

Journal Articles

Outpatient administration of epcoritamab monotherapy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Results from EPCORE NHL-6 by race and ethnicity

Blood (2025) 146 (Supplement 1): 1959.

https://doi.org/10.1182/blood-2025-1959

Published: 2025

Journal Articles

Efficacy and Safety of Epcoritamab Monotherapy in Patients with Relapsed or Refractory LBCL Not Previously Exposed to CAR T: Subanalysis of the Epcore NHL-1 Trial

Yasmin H. Karimi, Michael Roost Clausen, David John Lewis, Wojciech Jurczak, Michelle Poon, Tae Min Kim, Young Rok Do, Pieternella Lugtenburg, Kristin Conte, David Soong, Barbara D'Angelo Månsson, Zhu Li, Christian Eskelund, Martin Hutchings

Blood (2024) 144 (Supplement 1): 1737.

https://doi.org/10.1182/blood-2024-199225

Published: 2024

Journal Articles

Phase 2 Trial to Evaluate Safety of Subcutaneous Epcoritamab Monotherapy in the Outpatient Setting Among Patients with Relapsed or Refractory Diffuse Grade 1-3a Large B-Cell and Follicular Lymphoma (EPCORE NHL-6)

Jeff P. Sharman, Ralph V. Boccia, Thomas Doerr, Kristin Conte, Yang Bai, Brian Elliott, David J. Andorsky

Blood (2022) 140 (Supplement 1): 9491–9492.

https://doi.org/10.1182/blood-2022-157575

Published: 2022

Journal Articles

Association of Baseline and Postinfusion Biomarkers with Safety and Efficacy Endpoints in Patients Treated with Orvacabtagene Autoleucel (orva-cel; JCARH125) in the Phase 1/2 Evolve Study (NCT03430011)

Julia Piasecki, BA, Todd Devries, PhD, Aditya Radhakrishnan, PhD, Yan Li, PhD, Mark Heipel, BS, Brian A. Fox, PhD, Valeria Beckett, MS, Mariana Cota Stirner, MD PhD, Kristin Conte, MPH, Thomas Doerr, MSc, Sham Mailankody, MBBS, Sandy W. Wong, MD, Philip L. McCarthy, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-137786

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Exposure to epcoritamab is associated with improved T-cell functionality and dynamic changes in CD8+ T-cells in diffuse large B-cell lymphoma: Insights from epcore NHL-6

Outpatient administration of epcoritamab monotherapy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Results from EPCORE NHL-6 by race and ethnicity

Efficacy and Safety of Epcoritamab Monotherapy in Patients with Relapsed or Refractory LBCL Not Previously Exposed to CAR T: Subanalysis of the Epcore NHL-1 Trial

Phase 2 Trial to Evaluate Safety of Subcutaneous Epcoritamab Monotherapy in the Outpatient Setting Among Patients with Relapsed or Refractory Diffuse Grade 1-3a Large B-Cell and Follicular Lymphoma (EPCORE NHL-6)

Association of Baseline and Postinfusion Biomarkers with Safety and Efficacy Endpoints in Patients Treated with Orvacabtagene Autoleucel (orva-cel; JCARH125) in the Phase 1/2 Evolve Study (NCT03430011)

Email alerts

ASH Publications

American Society of Hematology

Update search

Exposure to epcoritamab is associated with improved T-cell functionality and dynamic changes in CD8+ T-cells in diffuse large B-cell lymphoma: Insights from epcore NHL-6

Outpatient administration of epcoritamab monotherapy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Results from EPCORE NHL-6 by race and ethnicity

Efficacy and Safety of Epcoritamab Monotherapy in Patients with Relapsed or Refractory LBCL Not Previously Exposed to CAR T: Subanalysis of the Epcore NHL-1 Trial

Phase 2 Trial to Evaluate Safety of Subcutaneous Epcoritamab Monotherapy in the Outpatient Setting Among Patients with Relapsed or Refractory Diffuse Grade 1-3a Large B-Cell and Follicular Lymphoma (EPCORE NHL-6)

Association of Baseline and Postinfusion Biomarkers with Safety and Efficacy Endpoints in Patients Treated with Orvacabtagene Autoleucel (orva-cel; JCARH125) in the Phase 1/2 Evolve Study (NCT03430011)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only